Longitudinal analyses using <sup>18</sup>F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.

Authors:
Cong Y; Lee JH; Perry DL; Cooper K; Wang H and 30 more

Journal:
Antiviral Res

Publication Year: 2023

DOI:
10.1016/j.antiviral.2023.105605

PMCID:
PMC10105383

PMID:
37068595

Journal Information

Full Title: Antiviral Res

Abbreviation: Antiviral Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Anti-Infective Agents

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"fig s1 data availability data will be made available on request."

Code Sharing
Evidence found in paper:

"Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

Evidence found in paper:

"Funding This work was supported in part through Laulima Government Solutions, LLC, prime contract with the 10.13039/100000002National Institutes of Health (10.13039/100000002NIH) 10.13039/100000060National Institute of Allergy and Infectious Diseases (10.13039/100000060NIAID) [contract number HHSN272201800013C]. Y.C., D.L.P, K.C., H.W., S.D., D.X.L., I.M.F., C.B., J.S., R.A., A.S., J.L., N.S., R.H., N.I., T.B., D.D.L., L.M.H., R.B., D.R., J.W., J.R.K., and M.R.H. performed this work as employees of Laulima Government Solutions, LLC. J.L. and A.W.H. performed this work as employees of Tunnell Government Services (10.13039/100011764TGS), a subcontractor of Laulima Government Solutions, LLC under Contract No. HHSN272201800013C. This work was also supported in part with federal funds from the 10.13039/100000002NIH 10.13039/100000054National Cancer Institute (10.13039/100000054NCI) [contract number 75N91019D00024, Task Order No. 75N91019F00130]. J.S. was supported by the Clinical Monitoring Research Program Directorate, 10.13039/100012728Frederick National Laboratory for Cancer Research, sponsored by 10.13039/100000054NCI. Support was also provided by a contract between the 10.13039/100006630Utah State University and the 10.13039/100000002NIH 10.13039/100000060NIAID 10.13039/100015691Division of Microbiology and Infectious Diseases (10.13039/100015691DMID) Virology Branch [contract number HHSN272201700041I, task order 75N93020F00001]. This work was also supported by the 10.13039/100000002NIH 10.13039/100000060NIAID Division of Intramural Research. The views and conclusions contained in this document are those of the authors and should not be interpreted as necessarily representing the official policies, either expressed or implied, of the U.S. Department of Health and Human Services or of the institutions and companies affiliated with the authors, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The animal study protocol was reviewed and approved by the NIH NIAID DCR IRF-Frederick Animal Care and Use Committee in compliance with all applicable federal regulations governing the protection of animals and research."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025